spacer
home > epc > spring 2017 > risky business
PUBLICATIONS
European Pharmaceutical Contractor

Risky Business

The globalisation of clinical trials and speciality pharmaceutical commercialisation, along with the rise of complex biologicalbased drug therapies, presents a host of opportunities for manufacturers. However, today’s mobile supply chain also comes with substantial risks. If overlooked, it can leave manufacturers, investors and an industry worth approximately $1.1 trillion exposed to potentially significant losses.

Managing the transportation of biopharmaceutical logistics cost almost $79 billion in 2016, with temperature-controlled products accounting for nearly $13 billion, according to Pharmaceutical Commerce’s annual Biopharma Cold Chain Sourcebook. With a growth rate of 8-9% year-on-year, spending on temperature-controlled logistics is predicted to rise to almost $17 billion by 2020, and the non-cold chain is estimated at $77 billion.

Such expense necessitates the identification and qualification of investment to mitigate mounting risks.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Nils Markmann is Vice President of Global Operations at World Courier and is responsible for the daily management of their global operation in terms of networkwide implementation and adherence to global standards, as well as for ensuring consistent operational excellence throughout the company’s 140 offices. Formerly General Manager of Operations for World Courier Germany, Nils has been with the company since 1995.
spacer
Nils Markmann
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

£1 Billion Savings Opportunity and Value to the UK Economy from SBRI Healthcare Innovation Programme

An NHS England funded initiative to develop products that address unmet health needs, today released its annual report that shows how the programme has created a pipeline of innovations that could bring the NHS £1 billion of savings.
More info >>

White Papers

Case Study: Getting the Client’s Trust - Oncology Program

Cmed Clinical Services

Five years ago, a biopharmaceutical company chose Cmed to conduct a phase II oncology study. Cmed’s performance of the study and the good relationship established with the Client led Cmed to be awarded a second oncology trial which a couple of years ago was followed by a third, fourth and fifth.
More info >>

 
Industry Events

Cell & Gene Exchange 2017

22-23 May 2017, 1300 Pennsylvania Ave NW Washington, DC 20004

The Cell & Gene Exchange brings together leaders from patient advocacy groups, industry, academia and government to network, exchange ideas and explore partnership opportunities. This partnering conference will facilitate conversations among patient groups and key stakeholders to advancing potentially curative therapies for life-threatening diseases.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement